For millions of Americans, the pain and debilitation of rheumatoid arthritis is significant. Impairing activities of daily living, many Americans find great difficulty in controlling the complications associated with rheumatoid arthritis, often using a combination approach of prescription drugs and therapy.
In the treatment of rheumatoid arthritis, the primary concern is the progressive deterioration of bone and joint health. With FDA approval of an antirheumatic drug, Arava, many rheumatoid arthritis sufferers are experiencing not only an improvement in symptoms but also a decrease in the deterioration of the bone and joint health.
Avara, manufactured and distributed by Aventis Pharmaceuticals, Inc., lends its success to the improvement of rheumatoid arthritis by reducing the inflammation and swelling in and around the bones and joints and slows the rate of deterioration in the bones and joints, often within three to six months of treatment. Considered a disease-modifying antirheumatic drug (DMARD), Avara is leading the way in arthritis treatment for many arthritis sufferers.
Dosing of Avara is also quite simple in that only one dose is required per day. While Avara is not a cure for rheumatoid arthritis, it can supply a significant improvement in this once-per-day dosing usually in 10 to 20 milligram tablets after starting the program with three days of 100 milligram doses.
Because there is no cure for rheumatic arthritis, Avara is an FDA approved drug that may be required for the entire life span. For this reason, it is important to establish a routine in which the Avara dosing is utilized on a daily basis.
As with most FDA approved drugs, the use of Avara, in the fight against the bone and joint deterioration of rheumatoid arthritis, should not be used by some individuals. Women who are pregnant, or may become pregnant, should avoid using Avara. Additionally, individuals with immuno-suppressive disorders, liver disorders or those with complications involving blood disorders should be screened and monitored closely when using Avara. The side effect most commonly seen, among all patients, is diarrhea, rash and even loss of hair. However, these side effects are minimal, accounting for less than 20 percent of the population.
As with any progressive disease, finding methods to offset life altering complications is the primary focus of care. In the case of rheumatoid arthritis, patients should consider using Avara in the fight against general inflammation and swelling but also to decrease the risk of bone and joint deterioration in the long term.